Blue Owl Capital Holdings LP Cuts Stock Holdings in Disc Medicine, Inc. (NASDAQ:IRON)

Blue Owl Capital Holdings LP reduced its stake in Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 31.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 120,260 shares of the company's stock after selling 55,000 shares during the period. Disc Medicine comprises approximately 1.8% of Blue Owl Capital Holdings LP's investment portfolio, making the stock its 14th largest position. Blue Owl Capital Holdings LP owned 0.40% of Disc Medicine worth $7,624,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in IRON. FMR LLC boosted its stake in shares of Disc Medicine by 358.7% in the 4th quarter. FMR LLC now owns 1,866,248 shares of the company's stock valued at $118,320,000 after purchasing an additional 1,459,434 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Disc Medicine by 23.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,394,637 shares of the company's stock valued at $88,421,000 after purchasing an additional 262,690 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Disc Medicine in the 4th quarter valued at approximately $5,579,000. Renaissance Technologies LLC acquired a new stake in shares of Disc Medicine in the 4th quarter valued at approximately $5,479,000. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Disc Medicine by 160.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 139,720 shares of the company's stock valued at $8,856,000 after purchasing an additional 86,154 shares in the last quarter. 83.70% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Mona Ashiya sold 202,146 shares of Disc Medicine stock in a transaction on Monday, March 10th. The shares were sold at an average price of $54.29, for a total value of $10,974,506.34. Following the completion of the sale, the director now owns 208,742 shares in the company, valued at $11,332,603.18. The trade was a 49.20 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Jonathan Yen-Wen Yu sold 1,610 shares of Disc Medicine stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $54.58, for a total transaction of $87,873.80. Following the completion of the sale, the chief operating officer now owns 40,555 shares of the company's stock, valued at $2,213,491.90. This represents a 3.82 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 361,690 shares of company stock worth $19,648,094 in the last quarter. 4.24% of the stock is owned by corporate insiders.

Disc Medicine Stock Up 1.6 %

Disc Medicine stock traded up $0.73 during mid-day trading on Tuesday, hitting $46.89. 86,320 shares of the stock were exchanged, compared to its average volume of 344,254. Disc Medicine, Inc. has a 12 month low of $27.39 and a 12 month high of $68.73. The firm's fifty day simple moving average is $48.38 and its two-hundred day simple moving average is $55.12. The stock has a market capitalization of $1.62 billion, a price-to-earnings ratio of -11.76 and a beta of 0.77.

Disc Medicine (NASDAQ:IRON - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $0.08. As a group, analysts forecast that Disc Medicine, Inc. will post -4.07 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. Cantor Fitzgerald raised their price target on shares of Disc Medicine from $99.00 to $132.00 and gave the company an "overweight" rating in a research note on Tuesday, March 18th. TD Cowen started coverage on shares of Disc Medicine in a report on Thursday, February 27th. They issued a "buy" rating for the company. Scotiabank raised their price objective on shares of Disc Medicine from $73.00 to $75.00 and gave the company a "sector outperform" rating in a report on Monday, March 3rd. Morgan Stanley reiterated an "overweight" rating and issued a $85.00 price objective on shares of Disc Medicine in a report on Friday, March 7th. Finally, Stifel Nicolaus raised their price objective on shares of Disc Medicine from $90.00 to $94.00 and gave the company a "buy" rating in a report on Friday, January 24th. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $93.80.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.